Table 1.
Baseline Characteristics, Presentation, and Uses of In‐hospital Procedures and Medications
| United States | South Korea | |
|---|---|---|
| No. of patients | 133 835 | 7901 |
| No. of participating hospitals | 433 | 72 |
| Demographics | ||
| Median age, y (1Q, 3Q) | 67 (56, 78) | 67 (56, 75) |
| Female sex, % | 38.5 | 33.0 |
| Median BMI, kg/m2 (1Q, 3Q) | 28.4 (24.8, 32.8) | 23.8 (21.8, 25.8) |
| Risk factors, % | ||
| Current smoker | 30.1 | 40.9 |
| History of HTN | 76.3 | 55.1 |
| DM | 35.1 | 31.6 |
| Dyslipidemia | 62.5 | 13.8 |
| Prior CVD/procedures, % | ||
| Prior MI | 28.9 | 7.5 |
| Prior CHF | 16.8 | 3.3 |
| Prior PCI | 25.3 | 7.2 |
| Prior CABG | 19.1 | 1.4 |
| Cerebrovascular disease | 14.8 | 9.0 |
| PAD | 12.4 | 1.1 |
| Initial vital signs | ||
| Median SBP, mm Hg (1Q, 3Q) | 145 (125, 166) | 130 (110, 150) |
| Median heart rate, bpm (1Q, 3Q) | 83 (70, 98) | 77 (67, 89) |
| ECG at presentation, % | ||
| ST depression or transient elevation | 26.3 | 21.0 |
| T‐wave changes | 14.1 | 15.8 |
| No ST‐ or T‐wave changes | 58.8 | 52.1 |
| Signs/symptoms of CHF | 20.2 | 27.5 |
| Cardiogenic shock | 1.8 | 2.7 |
| Laboratory findings | ||
| Median Cr, mg/dL (1Q, 3Q) | 1.1 (0.9, 1.4) | 1.0 (0.8, 1.2) |
| In‐hospital mortality, % | 4.0 | 4.5 |
| Extent of coronary disease in patients who underwent angiography, % | ||
| 1‐vessel disease | 27.7 | 33.4 |
| 2‐vessel disease | 28.7 | 27.2 |
| 3‐vessel disease | 34.8 | 30.6 |
| Medications, % | ||
| Aspirin | 96.8 | 94.4 |
| P2Y12 inhibitors | 74.1 | 92.3 |
| GP IIb/IIIa inhibitors | 33.1 | 8.0 |
| Anticoagulants | ||
| Heparin | 84.8 | 80.7a |
| Bivalirudin | 16.7 | NAa |
| Fondaparinux | 0.4 | NAa |
| Argatroban | 0.1 | 0.1a |
| β‐Blocker | 92.6 | 80.0 |
| ACEI/ARB | 68.5 | 82.0 |
| Statin | 85.1 | 77.6 |
| In‐hospital procedures, % | ||
| Angiography | 79.6 | 91.3 |
| PCI | 47.4 | 74.8 |
| DES among PCI with stent | 67.2 | 92.7 |
| CABG | 11.4 | 4.4 |
| Total revascularization | 58.1 | 77.9 |
Abbreviations: 1Q, first quartile; 3Q, third quartile; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; Cr, creatinine; CVD, cardiovascular disease; DES, drug‐eluting stent; DM, diabetes mellitus; ECG, electrocardiogram; GP, glycoprotein; HTN, hypertension; MI, myocardial infarction; NA, not available; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
a
Results from 2007 to 2010, total revascularization was either PCI or CABG.